Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion

Authors Maria Domenica Cappellini

Published 15 May 2007 Volume 2007:3(2) Pages 291—299

Maria Domenica Cappellini

Universita di Milano, Fondazione Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena IRCCS, Milan, Italy

Abstract: Although blood transfusions are important for patients with anemia, chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload lead to significant morbidity and mortality, if untreated. Although the current reference standard iron chelator deferoxamine has been used clinically for over four decades, its effectiveness is limited by a demanding therapeutic regimen that leads to poor compliance. Deferasirox (Exjade®, ICL670, Novartis Pharma AG, Basel, Switzerland) is a once-daily, oral iron chelator approved for the treatment of transfusional iron overload in adult and pediatric patients. The efficacy and safety of deferasirox have been established in a comprehensive clinical development program involving patients with various transfusion-dependent anemias. Deferasirox has a dose-dependent effect on iron burden, and is as efficacious as deferoxamine at comparable therapeutic doses. Deferasirox therapy can be tailored to a patient’s needs, as response is related to both dose and iron intake. Since deferasirox has a long half-life and is present in the plasma for 24 hours with once-daily dosing, it is unique in providing constant chelation coverage with a single dose. The availability of this convenient, effective, and well tolerated therapy represents a significant advance in the management of transfusional iron overload.

Keywords: Exjade, deferasirox, transfusional iron overload, effective.

Download Article [PDF] 

Readers of this article also read:

A characteristic optic disc appearance associated with myopia in subjects with Graves' ophthalmopathy and in subjects with primary open-angle glaucoma

Yamazaki S, Inoue R, Tsuboi T, Kozaki A, Inoue T, Inoue T, Inoue Y

Clinical Ophthalmology 2013, 7:47-53

Published Date: 7 January 2013

Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki

Geoffrey S Dow, Alan J Magill, Colin Ohrt

Therapeutics and Clinical Risk Management 2008, 4:803-819

Published Date: 8 August 2008

Towards a new standard of perioperative fluid management

Conor J Shields

Therapeutics and Clinical Risk Management 2008, 4:569-571

Published Date: 11 April 2008

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

Bianca Devitt, Sue-Anne McLachlan

Therapeutics and Clinical Risk Management 2008, 4:453-458

Published Date: 11 April 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008

Decitabine in the treatment of myelodysplastic syndromes

Hussain I Saba

Therapeutics and Clinical Risk Management 2007, 3:807-817

Published Date: 15 November 2007

How should we measure medication adherence in clinical trials and practice?

Jeannie K Lee, Karen A Grace, Terri G Foster, Monica J Crawley, Goldina I Erowele, et al

Therapeutics and Clinical Risk Management 2007, 3:685-690

Published Date: 15 September 2007

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:335-336

Published Date: 15 December 2006